ReviewPlant-environment interactions (Hoboken, N.J.)2025
Questions and Consequences of Omics in Genetically Engineered Crop Regulation.
Review in Plant-environment interactions (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-targeted metabolite profiling reveals substantial equivalence of omega-3 enrichedGM crops & food · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2016, a National Academies of Sciences, Engineering, and Medicine advisory committee proposed omics technologies as one possible adequate response to the regulatory challenges posed by gene editing and synthetic biology. This paper presents a set of questions that would need to be answered to integrate omics experiments and data into crop regulatory systems. These questions concern both experimental practice and how omics-experimental and regulatory systems intersect. We anticipate that the chosen answers to these questions will impact the scientific validity, regulatory burden, and usefulness for forecasting risk in nuanced ways. In doing so, we conclude that the integration of omics technologies into regulatory systems poses an array of more-than-technical dilemmas whose management will require cross-sector collaboration and innovative approaches to socio-technical decision-making.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.